Stephanie Horn-Warnock has officially filed a Form 3, confirming her position as Chief Financial Officer (CFO), Treasurer, and Corporate Secretary at Tempest Therapeutics, Inc. This filing is significant as it reflects her role in the company's leadership and governance.

Background

Tempest Therapeutics, Inc. is a company operating in the pharmaceutical preparations industry, with a focus on developing innovative therapies. The company is incorporated in Delaware and has its business address at 2000 Sierra Point Parkway, Suite 400, Brisbane, CA. The recent filing was made on November 3, 2026, and is part of their ongoing commitment to transparency and regulatory compliance.

What the Filing Says

The filing states that Horn-Warnock is not a director but holds an officer position, specifically as CFO, Treasurer, and Corporate Secretary. Her signature is included, confirming her role and the date of the filing.

Impact

This filing may affect various stakeholders, including investors, employees, and regulatory bodies, as it highlights the leadership structure within Tempest Therapeutics. The pharmaceutical industry often scrutinizes such changes, as they can impact corporate governance and strategic direction.

What's Next

The filing does not say what happens next.

Ownership Details

According to the filing, Horn-Warnock has reported ownership of one security in Tempest Therapeutics, Inc. This indicates her direct involvement and investment in the company, which may further align her interests with those of other stakeholders.

Company Information

Tempest Therapeutics, Inc. is classified under the Standard Industrial Classification (SIC) code for Pharmaceutical Preparations, specifically 2834. This classification underscores the company's focus on the development of therapeutic solutions within the life sciences sector.

Previous Company Names

The filing also notes that Tempest Therapeutics was formerly known as Millendo Therapeutics, Inc., with a name change occurring on December 7, 2018. Additionally, the company was previously called OvaScience, Inc., which underwent a name change on March 8, 2012. These historical changes may reflect the company's evolving focus and strategic direction in the pharmaceutical industry.